ERBB2 and breast cancer: Multi-parameter assays (Oncotype, Endopredict, Prosigna, BCI, and perhaps Mammaprint) have demonstrated validity and clear clinical utility for prognosis in low risk breast cancer (ER positive, HER-2 negative, node negative).